Literature DB >> 6326014

Lonidamine alone and in combination with other chemotherapeutic agents in the treatment of cancer patients.

G Pacilio, G Carteni, M Biglietto, M De Cesare.   

Abstract

The tolerance and antitumor activity of Lonidamine administered alone and in combination with other anticancer agents were studied. Myalgia was the most frequent side effect; there were no changes in the hematological parameters attributable to Lonidamine administration. 1 partial response out of the 16 patients treated with Lonidamine alone was observed.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6326014     DOI： 10.1159/000225897

Source DB:  PubMed          Journal:  Oncology        ISSN： 0030-2414            Impact factor:   2.935


  4 in total

Review 1.  Interaction of oligomeric breast cancer resistant protein (BCRP) with adjudin: a male contraceptive with anti-cancer activity.

Authors:  Yan Ho Cheng; Pranitha Jenardhanan; Premendu P Mathur; Xiaojing Qian; Weiliang Xia; Bruno Silvestrini; Chuen Yan Cheng
Journal:  Curr Mol Pharmacol       Date:  2014       Impact factor: 3.339

2.  Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro.

Authors:  K W Rosbe; T W Brann; S A Holden; B A Teicher; E Frei
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Lonidamine induces intracellular tumor acidification and ATP depletion in breast, prostate and ovarian cancer xenografts and potentiates response to doxorubicin.

Authors:  Kavindra Nath; David S Nelson; Daniel F Heitjan; Dennis B Leeper; Rong Zhou; Jerry D Glickson
Journal:  NMR Biomed       Date:  2014-12-12       Impact factor: 4.044

4.  Phase II study of lonidamine in metastatic breast cancer.

Authors:  P Pronzato; D Amoroso; G Bertelli; P F Conte; M P Cusimano; G B Ciottoli; M Gulisano; R Lionetto; R Rosso
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.